In this article, we discuss the Jeff Bezos Stock Portfolio: Top 10 Stock Picks.
Jeff Bezos is a visionary entrepreneur, investor, and engineer who fundamentally reshaped global commerce and digital infrastructure. Born in 1964, Bezos graduated from Princeton University before embarking on a highly successful early career on Wall Street. However, recognizing the explosive, exponential growth of the early internet, he made the calculated gamble to leave his lucrative finance position. In 1994, he founded Amazon out of his Seattle garage. Since 2021, Bezos redirected his intense operational energy toward deep-tech exploration, aerospace engineering, and advanced computing. His commercial space venture, Blue Origin, focuses heavily on developing reusable launch vehicles and infrastructure to facilitate heavy industry moving off-planet. Furthermore, his personal venture capital fund, Bezos Expeditions, has continued to back foundational tech giants.
READ MORE: Michael Burry Stock Portfolio: Top 8 Stock Picks in 2026.
Bezos’s net worth hovers around $284 billion, securing his position at the apex of global wealth. Currently, his core focus has pivoted sharply toward artificial intelligence and automation. Bezos serves as the co-CEO of Prometheus, a newly emerged, high-profile AI startup dedicated to automating physical engineering and design workflows. His contemporary investment philosophy concentrates heavily on combining massive computing power with physical manufacturing, positioning artificial intelligence as the definitive connective tissue across all his corporate holdings. Through his unmatched execution of long-term strategies, Bezos remains an essential architect of the modern global economy, driving technological advancement from earth to low-orbit space.
READ MORE: Graham Stephan Stock Portfolio: Top 11 Stocks.
Our Methodology
It is important to clarify that the stocks listed below were picked from the publicly available information around Jeff Bezos and his investments. He has explicitly mentioned some of his private holdings during public appearances while only alluding to others. However, based on a careful assessment of the data, the stocks listed below largely align with his investment philosophy. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q1 2026 database of 1041 elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Jeff Bezos Stock Portfolio: Top Stock Picks
10. Denali Therapeutics Inc. (NASDAQ:DNLI)
Jeff Bezos established a strategic relationship with Denali Therapeutics Inc. (NASDAQ:DNLI) through his personal venture capital entity, Bezos Expeditions, identifying the biotech firm as a premier player in neurodegenerative disease research. Bezos backed Denali during its early private financing cycles prior to its 2017 initial public offering, aligning his capital with the company’s quest to conquer the blood-brain barrier. Denali specializes in developing engineered biotherapeutics using its proprietary Transport Vehicle (TV) platform, which enables large therapeutic molecules like antibodies and enzymes to cross into the central nervous system efficiently. Bezos’s investment reflected his broader philanthropic and venture interest in cellular longevity and structural solutions to complex chronic diseases.
Financial success for Denali Therapeutics Inc. (NASDAQ:DNLI) centers on the clinical validation and commercial scaling of its Transport Vehicle technology, which has significantly outpaced legacy delivery methods. The company’s Q1 2026 trajectory highlights high-value ongoing development milestones and strategic structural collaborations with global pharmaceutical giants like Sanofi and Biogen, which continue to derisk its pipeline. Investors are optimistic about the regulatory pipeline for its Hunter syndrome therapy, which showcases the platform’s unique ability to deliver systemic enzymatic fixes directly to brain tissue.
